Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 3, 2003, Pages 249-254

  Mihm, U ^a   Sarrazin, C ^a   Herrmann, E ^b   Teuber, G ^c   Von Wagner, M ^a   Kronenberger, B ^a   Zeuzem, Stefan ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Drug resistance; Long term lamivudine; Post treatment follow up

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; MALE; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; SEROCONVERSION; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LONG-TERM CARE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; VIRUS REPLICATION;

EID: 0037353088     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37902     Document Type: Article

References (38)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
2. Thierfelder W, Meisel H, Schreier E et al. Prevalence of antibodies to hepatitis A, hepatitis B and hepatitis C viruses in the German population. Gesundheitswesen 1999; 61 (Spec No): S110-S114
3. Wong DK, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323
4. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109
5. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001; 8: 311-321
6. Chang TT, Lai CL, Liaw YF et al. Incremental increase in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. Antiviral Therapy 2000; 5 (Suppl. 1): 44A
7. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263
8. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087
9. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
10. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532
11. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180
12. Santantonio T, Mazzola M, Iacovazzi T et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-306
13. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-896
14. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716
15. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-851
16. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834
17. Chang TT, Lai CL, Liaw YF et al. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine. Hepatology 1999; 30: 420A
18. Liaw YF, Lai CL, Leung N et al. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in Asia. Gastroenterology 1998; 114: A1289
19. Teuber G, Lohr HF, Kallinowski B et al. Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B. Dtsch Med Wochenschr 2001; 126: 97-102
20. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435
21. Zeuzem S. Overview of commercial HBV assay systems. In: Hamatake R and Lau J (Hrsg). Methods in Molecular Medicine: Hepatitis B Protocols. Totowa: Humana Press in press
22. Dienstag JL, Perrillo RP, Schiff ER et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661
23. Tassopoulos NC, Volpes R, Pastore G et al. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B. J Hepatol 1999; 30 (suppl 1): 117A
24. Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-806
25. Papatheodoridis GV, Dimou E, Laras A et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-226
26. Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-1153
27. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-568
28. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002; 66: 435-451
29. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-572
30. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633
31. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723
32. Gilson RJ, Chopra KB, Newell AM et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6: 387-395
33. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134
34. Peters MG, Singer G, Howard T et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912-1914
35. Yang H, Westland CE, Delaney WE et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-473
36. van Bommel F, Wunsche T, Schurmann D et al. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36: 507-508
37. Tassopoulos NC, Hadziyannis SJ, Cianciara J. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34: 340A
38. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-774